Ketamine, Psilocybin and Brain Stimulation Offer New Hope for Treatment-Resistant OCD

Obsessive-compulsive disorder is one of the most disabling psychiatric conditions known to medicine, and for a substantial share of the people who live with it, the standard arsenal simply does not work. Selective serotonin reuptake inhibitors, the antidepressants most commonly prescribed at high doses for OCD, and exposure-based cognitive behavioral therapy, the psychological gold standard, leave many patients trapped in cycles of intrusive thoughts and compulsive rituals. A new narrative review published in Translational Psychiatry by researchers at the Medical University of Vienna, the University of Freiburg and the National Institute of Mental Health takes stock of what may come next: rapid-acting drugs such as ketamine and psilocybin, brain-stimulation techniques ranging from repetitive transcranial magnetic stimulation to surgically implanted deep brain stimulation electrodes, and an emerging biological storyline that ties early life stress, chronic inflammation and the body’s stress hormone system directly into the circuitry of the disorder.

The review, led by Johan Saelens and Christoph Kraus in Vienna with contributions from Juan Carlos Baldermann in Freiburg and Ioline D. Henter and Carlos A. Zarate Jr. at the NIMH, is deliberately broad. Rather than reporting a single trial, it synthesizes the current evidence on fast-onset and neuromodulatory interventions for patients whose OCD has resisted first-line treatment, and it frames those interventions through the lens of stress biology. That framing matters, the authors argue, because growing evidence links early adversity to neuroinflammatory pathways and dysregulation of the hypothalamic-pituitary-adrenal axis, the hormonal cascade that governs the body’s response to stress, in people with OCD. If stress systems help drive the illness, then treatments that rapidly reset those systems may do more than blunt symptoms; they may open entirely new therapeutic targets.

The pharmacological headline act is ketamine, an anesthetic that has already transformed thinking about rapid-acting antidepressants. At subanesthetic doses, ketamine blocks the N-methyl-D-aspartate receptor, a glutamate-gated ion channel, which triggers a downstream surge in synaptic plasticity and, within hours rather than weeks, measurable changes in mood and cognition. For OCD, the logic is similar but the target is different: cortico-striato-thalamo-cortical circuits, the feedback loops between cortex, striatum and thalamus that are thought to generate the repetitive, self-perpetuating loops of obsessions and compulsions. Preliminary clinical trials of ketamine in OCD have been encouraging, the review finds, but the results are mixed, and evidence on repeated dosing, the practical question of whether benefit can be sustained across multiple infusions, remains scarce.

Psilocybin, the psychoactive compound in so-called magic mushrooms, occupies a parallel position. As a serotonin 2A receptor agonist, psilocybin acutely disrupts rigid patterns of brain activity, including the hyperactive default mode network dynamics that have been implicated in rumination and obsessive thinking. Early studies suggest it may exert rapid-acting effects in OCD, and the compound has generated enormous public and scientific enthusiasm. Yet the review is careful: as with ketamine, the clinical trial base in OCD is preliminary, findings are inconsistent across studies, and the field lacks the repeated-dosing data needed to know whether a single psychedelic session can produce durable relief or whether controlled re-dosing protocols will be required. The authors also note that rigorous trial design is particularly difficult here, because the unmistakable subjective effects of psychedelics complicate blinding and placebo control.

On the device side, the review examines repetitive transcranial magnetic stimulation, a noninvasive technique that uses magnetic pulses to modulate cortical excitability. rTMS is already approved in several jurisdictions for psychiatric indications, and for OCD the typical target is the medial prefrontal and anterior cingulate cortex, key nodes of the cortico-striato-thalamo-cortical loop. The evidence base is growing, with some trials showing meaningful symptom reduction, but effect sizes vary across protocols and stimulation parameters, and questions about optimal coil placement, session frequency and maintenance treatment remain open. Deep brain stimulation, by contrast, is invasive: electrodes are surgically implanted into nodes such as the nucleus accumbens or the anterior limb of the internal capsule, regions through which the pathological loops of OCD are thought to funnel. In severely ill, treatment-refractory patients, DBS has produced striking remissions in some cases, and the review positions it as the most aggressive but also the most targeted option in the neuromodulatory toolkit.

What unites these disparate approaches, the authors suggest, is speed. Conventional pharmacotherapy for OCD typically requires ten to twelve weeks of high-dose SSRI treatment before benefit can be judged, and even then a large percentage of patients do not respond. Rapid-acting agents and neuromodulation compress that timeline dramatically, raising the possibility of intervening at moments of acute distress, of using fast-onset treatments to open a window during which psychotherapy can take hold, and of combining modalities, for example pairing a glutamatergic drug with exposure-based therapy or with stimulation, to achieve effects neither could deliver alone.

The stress-reduction thread running through the review gives this pharmacological story a biological backbone. Early life stress is increasingly recognized as a risk factor for OCD, and the mechanisms proposed are concrete: chronic stress activation can sensitize neuroimmune signaling, producing neuroinflammation that alters synaptic function in cortico-striatal circuits, while dysregulation of the hypothalamic-pituitary-adrenal axis distorts cortisol rhythms and the feedback loops that normally terminate a stress response. Rapid-acting treatments may interact with these systems directly. Ketamine’s effects on stress-related signaling and on inflammatory mediators have been documented in depression research, and the review argues that similar mechanisms deserve systematic study in OCD, where measuring inflammatory markers and HPA-axis activity could identify which patients are most likely to respond and which targets are genuinely engaged by treatment.

The authors are candid about the limits of the evidence. This is a narrative review, not a meta-analysis, and the trials it surveys are small, heterogeneous and in some cases uncontrolled. Mixed results across ketamine and psilocybin studies mean that neither can yet be recommended as standard care for treatment-resistant OCD, and repeated-dosing data, the cornerstone of any chronic treatment strategy, are thin. Neuromodulatory findings, meanwhile, span a wide range of stimulation targets and protocols, making cross-study comparison difficult. The review’s contribution is therefore less a verdict than a map: it consolidates what is known, highlights where the evidence is weakest, and proposes stress-related mechanisms as a unifying framework for the next generation of studies.

Those future directions are concrete. The authors call for adequately powered randomized trials of repeated-dose ketamine and psilocybin in OCD, for standardized neuromodulation protocols that can be compared across centers, and for studies that incorporate biological measures, inflammatory markers, HPA-axis indices and neuroimaging of cortico-striato-thalamo-cortical connectivity, so that treatment response can be understood mechanistically rather than observed statistically. Biomarker-driven stratification, in this vision, would allow clinicians to match patients to the intervention most likely to help them, whether that is a rapid-acting drug, a stimulation protocol or a combination.

For the millions of patients whose OCD has not yielded to SSRIs or cognitive behavioral therapy, the review offers something rare: a credible set of near-term possibilities grounded in identifiable brain circuits and stress biology rather than in trial and error. The work was supported in part by the Austrian Science Fund and by the Intramural Research Program of the National Institutes of Health, and it arrives at a moment when psychiatry is broadly rethinking how quickly, and through which mechanisms, severe psychiatric symptoms can be relieved. Whether ketamine infusions, psychedelic sessions or magnetic pulses ultimately earn a routine place in OCD care will depend on the trials the review calls for, but its central claim, that rapid relief for treatment-resistant patients is a realistic research goal rather than a distant hope, is now on the record in a peer-reviewed journal.

Subject of Research: Neuroscience

Article Title: Rapid-acting and neuromodulatory interventions for treatment-resistant OCD: clinical implications in stress reduction

Article References: Rapid-acting and neuromodulatory interventions for treatment-resistant OCD: clinical implications in stress reduction. (n.d.). https://doi.org/10.1038/s41398-026-04480-x

Image Credits: AI Generated

DOI: 10.1038/s41398-026-04480-x

Keywords: OCD, ketamine, psilocybin, deep brain stimulation, rTMS, treatment-resistant, HPA axis, neuroinflammation, Translational Psychiatry, Rapid-acting, neuromodulatory, interventions